Yelda TÜRKMENOĞLU, Hasan DURSUN, Ahmet İRDEM, Diğdem BEZEN, Biray ERTÜRK, Elif GÜNEY

Evaluation of S100A12 protein levels in children with familial Mediterranean fever

Background/aim: Familial Mediterranean fever (FMF), the most common autoinflammatory disease in children, is characterized by recurrent febrile episodes. FMF is known to progress with chronic inflammation, particularly during attack periods. This study aimed to investigate the relationship of S100A12, an inflammatory marker, with attacks and inflammatory events in FMF patients. Materials and methods: The study included 57 patients diagnosed with FMF, 43 in an attack-free period and 14 in an attack period, and 31 healthy children as the control group. Only white blood cell (WBC) count, C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), and S100A12 level were analyzed in the control group. In addition, serum amyloid A (SAA), and fibrinogen levels were measured, and a mutation analysis was performed in the patient group. The results were compared among the attack-free period, acute attack FMF and control groups. Results: The mean age of patients and control group was 10 (2.5–18) and 9.5 (2.5–16) years, respectively. The CRP (p = 0.001), S100A12 (p = 0.003) and ESR (p= 0.001) values differed significantly between the FMF and control groups. S100A12 level (p = 0.027), WBC count (p = 0.003), CRP level (p = 0.0001), ESR (p = 0.004), and fibrinogen level (p = 0.001) differed significantly between the acute attack and attack-free period groups. SAA level (p = 0.05), ESR (p = 0.001), fibrinogen level (p = 0.001), WBC count (p = 0.001), and S100A12 level (p = 0.027) were higher in M694V homozygous FMF patients than in other FMF patients. Conclusion: Patients with FMF had higher S100A12 levels than the control group, while the mean S100A12 concentration was higher in acute attack period patients than in attack-free period patients. S100A12 level might be an important indicator in the monitoring of chronic inflammation in patients with FMF.Key words: Children, familial Mediterranean fever, inflammation, S100A12

PDF

___

1. Ben-Chetrit and Levy. Familial Mediterranean fever. Lancet 1998; 351 (9103): 659-664. doi: 10.1016/S0140-6736(97)09408-7
2. Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E et al. EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases 2016; 75 (4): 644-651. doi: 10.1136/annrheumdis-2015-208690
3. Barut K, Sahin S, Adrovic A, Sinoplu AB, Yucel G et al. Familial Mediterranean fever in childhood: a single-center experience. Rheumatology International 2018; 38 (1): 67-74. doi: 10.1007/ s00296-017-3796-0
4. Yilmaz E, Ozen S, Balci B, Duzova A, Topaloglu R et al. Mutation frequency of familial Mediterranean fever and evidence for a high carrier rate in the Turkish population. European Journal of Human Genetics 2001; 9 (7): 553-555. doi: 10.1038/sj.ejhg.5200674
5. Pras E, Aksentijevich I, Gruberg L, Balow JE, Prosen L et al. Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. New England Journal of Medicine 1992; 326 (23): 1509-1513. doi.org/10.1056/ NEJM199206043262301
6. Tanatar A, Karadağ ŞG, Çakan M, Sönmez HE, Ayaz NA. Age of onset as an influencing factor for disease severity in children with familial Mediterranean fever. Modern Rheumatology 2021; 31 (1): 219-222. doi: 10.1080/14397595.2020.1719594
7. Chae JJ, Komarow HD, Cheng J, Wood G, Raben N et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Molecular Cell 2003; 11 (3): 591-604. doi: 10.1016/s1097-2765(03)00056-x
8. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117 (14): 3720-3732. doi: 10.1182/blood-2010-07-273417
9. Holzinger D, Foell D, Kessel C. The role of S100 proteins in the pathogenesis and monitoring of autoinflammatory diseases. Molecular and Cellular Pediatrics 2018; 5: 7. doi:10.1186/s40348- 018-0085-2
10. Šumová B, Cerezo LA, Szczuková L, Nekvindová L, Uher M et al. Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. Rheumatology International 2019; 39 (3): 469-478. doi: 10.1007/s00296-018- 4190-2
11. Brown KL, Lubieniecka JM, Armaroli G, Kessel K, Gibson KM et al. S100A12 Serum levels and PMN counts are elevated in childhood systemic vasculitis especially involving proteinase 3 specific anti-neutrophil cytoplasmic antibodies. Frontiers in Pediatrics 2018; 23 (6): 341. doi: 10.3389/fped.2018.00341
12. Wang X, Sun Z, Tian W, Piao C, Xie X et al. S100A12 is a promising biomarker in papillary thyroid cancer. Scientific Reports 2020; 10 (1): 1724. doi: 10.1038/s41598-020-58534-1
13. Demirci Sağlam G, Zamani A, Yosunkaya Ş, Kılınç İ. Serum S100A12 and S100B proteins are independent predictors of the presence and severity of obstructive sleep apnea. Turkish Journal of Medical Sciences 2019; 49 (3): 746-754. doi: 10.3906/ sag-1806-147
14. Foell D, Wittkowski H, Hammerschmidt I, Wulffraat NM, Schmeling H et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis & Rheumatology 2004; 50 (4): 1286-1295. doi: 10.1002/art.20125
15. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S et.al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis & Rheumatology 1997; 40 (10): 1879-1885. doi: 10.1002/art.1780401023
16. Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis & Rheumatology 2008; 58 (12): 3924-3931. doi: 10.1002/art.24137
17. Yamasaki Y, Takei S, Imanaka H, Kubota T, Nonaka Y et al. S100A12 and vascular endothelial growth factor can differentiate Blau syndrome and familial Mediterranean fever from systemic juvenile idiopathic arthritis. Clinical Rheumatology 2019; 38 (3): 835-840. doi: 10.1007/s10067-018- 4359-9
18. Kallinich T, Wittkowski H, Keitzer R, Roth J, Foell D. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Annals of the Rheumatic Diseases 2010; 69 (4): 677-682. doi: 10.1136/ ard.2009.114363
19. Taylan A, Gurler O, Toprak B, Sisman AR, Yalcin H et al. S1000A12, Chitotriosidase, and resolvin D1 as potential biomarkers of familial Mediterranean fever. Journal of Korean Medical Science 2015; 30 (9): 1241-1245. doi: 10.3346/ jkms.2015.30.9.1241
20. Lachmann HJ, Sengül B, Yavuzşen TU, Booth DR, Booth SE et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006; 45 (6): 746- 750. doi:10.1093/rheumatology/kei279
21. Korkmaz C, Ozdogan H, Kasapçopur O, Yazici H. Acute phase response in familial Mediterranean fever. Annals of the Rheumatic Diseases 2002; 61 (1): 79-81. doi: 10.1136/ ard.61.1.79
22. Bayram MT, Cankaya T, Bora E, Kavukçu S, Ülgenalp A et al. Risk factors for subclinical inflammation in children with Familial Mediterranean fever. Rheumatology International 2015; 35 (8): 1393-1398. doi: 10.1007/s00296-015-3227
23. Babaoglu H, Armagan B, Bodakci E, Satis H, Atas N et al. Predictors of persistent inflammation in familial Mediterranean fever and association with damage. Rheumatology (Oxford) 2021; 60 (1): 333-339. doi: 10.1093/rheumatology/keaa378
24. Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nature Reviews Rheumatology 2011; 7 (2): 105-112. doi: 10.1038/ nrrheum.2010.181
25. Kessel C, Holzinger D, Foell D. Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunol 2013; 147 (3): 229-241. doi: 10.1016/j.clim.2012.11.008
26. Gohar F, Orak B, Kallinich T, Jeske M, Lieber M et al. Correlation of secretory activity of neutrophils with genotype in patients with Familial Mediterranean Fever. Arthritis Rheumatology 2016; 68 (12): 3010-3022. doi: 10.1002/art.39784
27. Shenoi S, Ou JN, Ni C, Macaubas C, Gersuk VH et al. Comparison of biomarkers for systemic juvenile idiopathic arthritis. Pediatric Research 2015; 78 (5): 554-559. doi: 10.1038/ pr.2015.144
28. Lieber M, Kallinich T, Lohse P, Klotsche J, Holzinger D et al. Increased serum concentrations of neutrophil-derived protein S100A12 in heterozygous carriers of MEFV mutations. Clinical and Experimental Rheumatology 2015; 33 (6 Suppl. 94): 113- 116.
29. Nursal AF, Tekcan A, Kaya SU, Turkmen E, Yigit S. Mutational spectrum of the MEFV gene in AA amyloidosis associated with Familial Mediterranean Fever. Iranian Journal of Kidney Diseases 2016; 10 (3): 107-112.
30. Bilge ŞY, Sarı İ, Solmaz D, Şenel S, Emmungil H et al. The distribution of MEFV mutations in Turkish FMF patients: multicenter study representing results of Anatolia. Multicenter Study. Turkish Journal of Medical Sciences 2019; 49 (2): 472- 477. doi: 10.3906/sag-1809-100
31. Yilmaz E, Dinçel N, Sözeri B, Ozdemir K, Bulut IK et al. Familial Mediterranean fever in children from the Aegean region of Turkey: gene mutation frequencies and phenotypegenotype correlation. Turkish Journal of Medical Sciences 2015; 45 (6): 1198-1206. doi:10.3906/sag-1402-1
32. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K et al. In vivo regulation of interleukin 1beta in patients with cryopyrinassociated periodic syndromes. Journal of Experimental Medicine 2009; 206 (5): 1029-1036. doi: 10.1084/jem.20082481
33. Stoler I, Freytag J, Orak B, Unterwalder N, Henning S et al. Gene-dose effect of MEFV gain-of-function mutations determines ex vivo neutrophil activation in Familial Mediterranean Fever. Frontiers in Immunology 2020; 11: 716. doi: 10.3389/fimmu.2020.00716